DermGEN™ is the most advanced Acellular Dermal Matrix (ADM) product created using the most advanced decellularization process (prECM™).
It is created from donated human skin, processed to remove donor cell immunogenic proteins, and preserves the natural structure and composition of skin. What is produced is a sterile, regenerative scaffold that promotes a patient’s own cells to create new tissue and heal wounds.
Requires only 1 application for healing.
Incorporates into wound bed after 1 week.
Weekly dressing changes only required.
Complete healing seen in an average 3.3 weeks** (**-DFU patient study).
Used for chronic and acute dermal wounds.
20 YEARS OF R&D
DermGEN™ is the result of over 20 years of research and development identifying and addressing the deficiencies and shortcomings of past and present Acellular Dermal Matrix (ADM) products. Until now, there has not been a definition or standard to indicate what an ADM product should be, but DermGEN™ now defines the standard.
QUALITY & SAFETY
DermGEN™ is tested to meet Quality and Safety standards that have been directly linked to clinical performance. These standards must be met before any piece of DermGEN™ is sold. The quality and safety of DermGEN™ are further ensured through its manufacture using a first ever automated closed-environment system. The superiority of DermGEN™ has also been acknowledged through the first ever issuing of patent claims protecting the properties and composition of DermGEN™ defined by 14 individual measures.